Advertisement

The Management of Infection Stones

  • Manoj Monga
  • Sarah Tarplin

Abstract

“Infection stones,” or stones formed as a result of urinary tract infection (UTI) with a urease-producing organism, are more common in women and those with functional or anatomic abnormalities of the urinary tract. Infection stones may form staghorns and the prognosis is poor if left untreated. The primary therapeutic goal should be that the patient is stone-free. To that end, percutaneous nephrolithotomy (PCNL) or other modern endoscopic interventions, in addition to culture-specific antimicrobial therapy are required. Hydroxamic acid and long-term antibiotic therapy may be useful adjuncts in some patients. Sepsis following PCNL is an ongoing challenge and can occur despite prophylactic antibiotic administration and treatment of a positive pre-operative urine culture. Recent studies suggest that a longer course of antibiotics prior to PCNL may be beneficial in some patients. Stones formed due to a metabolic derangement can lead to infection by providing a nidus for bacterial growth or by causing obstruction. After collecting system decompression and delayed stone removal, it is important to identify and manage all risk factors for infection in patients with stones and concomitant infection.

Keywords

Spinal Cord Injury Neurogenic Bladder Asymptomatic Bacteriuria Percutaneous Nephrolithotomy Nephrostomy Tube 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Allan WR, Kumar A. Prophylactic mezlocillin for transurethral prostatectomy. Br J Urol. 1985;57(1):46–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Bag S, Kumar S, Taneja N, Sharma V, Mandal AK, Singh SK. One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. Urology. 2011;77(1):45–9. doi: 10.1016/j.urology.2010.03.025.CrossRefPubMedGoogle Scholar
  3. 3.
    Bichler KH, Eipper E, Naber K, Braun V, Zimmermann R, Lahme S. Urinary infection stones. Int J Antimicrob Agents. 2002;19(6):488–98.CrossRefPubMedGoogle Scholar
  4. 4.
    Borghi L, Nouvenne A, Meschi T. Nephrolithiasis and urinary tract infections: ‘the chicken or the egg’ dilemma? Nephrol Dial Transplant. 2012;27:3982–5.Google Scholar
  5. 5.
    Brown P. Management of urinary tract infections associated with nephrolithiasis. Curr Infect Dis Rep. 2010;12:450–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Cafferkey MT, Falkiner FR, Gillespie DM, Murphy DM. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother. 1982;9:471–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5(5):316–22. doi: 10.5489/cuaj.11214.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Daudon M, Doré JC, Jungers P, Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol Res. 2004;32(3):241–7. Epub 2004 May 4.CrossRefPubMedGoogle Scholar
  9. 9.
    Dogan HS, Sahin A, Cetinkaya Y, Akdogan B, Ozden E, Kendi S. Antimicrobial prophylaxis in percutaneous nephrolithotomy: prospective study in 81 patients. J Endourol. 2002;16(9):649–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Donnellan SM, Bolton DM. The impact of contemporary bladder management techniques on struvite calculi associated with spinal cord injury. BJU Int. 1999;84(3):280–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Eswara JR, Shariftabrizi A, Sacco D. Positive stone culture is associated with a higher rate of sepsis after endourological procedures. Urolithiasis. 2013;41:411–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Ferrandino MN, Pietrow PK, Preminger GM. Evaluation and medical management of urinary lithiasis. In: Wein AJ, Kavoussi LR, Novisk AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. Saunders: Elsevier; 2012. p. 1287–323.CrossRefGoogle Scholar
  13. 13.
    Friedlander J, Waingankar N, Okeke Z, Smith A. Stratification of risk factors for sepsis following endourological procedures. J Urol. 2011;185(4 Suppl):abstract 1548, 621.Google Scholar
  14. 14.
    Ghani KR, Sammon JD, Bhojani N, Karakiewicz PI, Sun M, Sukumar S, Littleton R, Peabody JO, Menon M, Trinh QD. Trends in percutaneous nephrolithotomy use and outcomes in the United States. J Urol. 2013;190(2):558–64. doi: 10.1016/j.juro.2013.02.036.CrossRefPubMedGoogle Scholar
  15. 15.
    Griffith DP, Gleeson MJ, Lee H, Longuet R, Deman E, Earle N. Randomized, double-blind trial of lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol. 1991;20(3):243–7.PubMedGoogle Scholar
  16. 16.
    Griffith DP, Khonsari F, Skurnick JH, et al. A randomized trial of acid the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol. 1988;140(2):318–24.PubMedGoogle Scholar
  17. 17.
    Griffith DP. Struvite stones. Kidney Int. 1978;13(5):372–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Gupta M, Ost MC, Shah JB, et al. Percutaneous management of upper urinary tract. In: Wein AJ, Kavoussi LR, Novisk AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. Saunders: Elsevier; 2007. p. 1548.Google Scholar
  19. 19.
    Herr HW. Intermittent catheterization in neurogenic bladder dysfunction. J Urol. 1975;113:477–9.PubMedGoogle Scholar
  20. 20.
    Iqbal MW, Youssef R, Neisius A, Kuntz N, Hanna J, Ferrandino MN, Preminger GM, Lipkin ME. Contemporary management of struvite stones using combined endourological and medical treatment: predictors of unfavorable clinical outcome. J Endourol. 2013. doi: 10.1089/end.2013-0257.ECC13.PubMedCentralGoogle Scholar
  21. 21.
    Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004;44(5):799–805.CrossRefPubMedGoogle Scholar
  22. 22.
    Kaefer M, Hendren WH, Bauer SB, Goldenblatt P, Peters CA, Atala A, Retik AB. Reservoir calculi: a comparison of reservoirs constructed from stomach and other enteric segments. J Urol. 1998;160(6 Pt 1):2187–90.PubMedGoogle Scholar
  23. 23.
    Koga S, Arakaki Y, Matsuoka M, Ohyama C. Staghorn calculi–long-term results of management. Br J Urol. 1991;68(2):122–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Lingeman JE, Siegel YI, Steele B. Metabolic evaluation of infected renal lithiasis: clinical relevance. J Endourol. 1995;9(1):51–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Mariappan P, Smith G, Bariol SV, Moussa SA, Tolley DA. Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol. 2005;173(5):1610–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Mariappan P, Smith G, Moussa SA, Tolley DA. One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. BJU Int. 2006;98(5):1075–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Mariappan P, Loong CW. Midstream urine culture and sensitivity test is a poor predictor of infected urine proximal to obstructive ureteric stone or infected renal stones. J Urol. 2004;171(6 Pt 1):2142–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Matlaga BR, Kim SC, Watkins SL, Kuo RL, Munch LC, Lingeman JE. J Urol. 2006 May;175(5):1716–9.Google Scholar
  29. 29.
    McAleer IM, Kaplan GW, Bradley JS, Carroll SF, Griffith DP. Endotoxin content in renal calculi. J Urol. 2003;169:1813–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Miano R, Germani S, Vespasiani G. Stones and urinary tract infections. Urol Int. 2007;79 Suppl 1:32–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.CrossRefPubMedGoogle Scholar
  32. 32.
    O’Keeffe NK, Mortimer AJ, Sambrook PA, et al. Severe sepsis following percutaneous or endoscopic procedures for urinary tract stones. Br J Urol. 1993;72:277–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Ost MC, Lee BR. Urolithiasis in patients with spinal cord injuries: risk factors, management, and outcomes. Curr Opin Urol. 2006;16(2):93–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Preminger GM, Assimos DG, Lingeman JE, Nakada SY, Pearle MS, Jr Wolf JS, AUA Nephrolithiasis Guideline Panel. Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendation. J Urol. 2005;173(6):1991–2000.CrossRefPubMedGoogle Scholar
  35. 35.
    Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J. Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. J Urol. 1991;146(4):955–60.PubMedGoogle Scholar
  36. 36.
    Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Resnick MI, Boyce WH. Bilateral staghorn calculi: patient evaluation and management. J Urol. 1980;123:338–41.PubMedGoogle Scholar
  38. 38.
    Resnick MI. Evaluation and management of infection stones. Urol Clin North Am. 1981;8(2):265–76.PubMedGoogle Scholar
  39. 39.
    Segura JW. Staghorn calculi. Urol Clin North Am. 1997;24(1):71–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Schaeffer AJ, Schaeffer EM. Infections of the urinary tract. In: Wein AJ, Kavoussi LR, Novisk AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. Saunders: Elsevier; 2012. p. 357.Google Scholar
  41. 41.
    Stamey TA, Condy M, Mihara G. Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections: biologic effects on the vaginal and rectal flora. N Engl J Med. 1977;296(14):780–3.CrossRefPubMedGoogle Scholar
  42. 42.
    Stamey TA. Pathogenesis and treatment of urinary tract infections. Baltimore: Williams & Wilkins Co; 1980. p. 430.Google Scholar
  43. 43.
    Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol. 1995;153(3 Pt 1):584–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Teichman JM, Long RD, Hulbert JC. Long-term renal fate and prognosis after staghorn calculus management. J Urol. 1995;153(5):1403–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Wagenlehner FM, Vahlensieck W, Bauer HW, Weidner W, Piechota HJ, Naber KG. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol. 2013;65(1):9–20.PubMedGoogle Scholar
  46. 46.
    Wang LP, Wong HY, Griffith DP. Treatment options in struvite stones. Urol Clin North Am. 1997;24(1):149–62.CrossRefPubMedGoogle Scholar
  47. 47.
    Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acid struvite nephrolithiasis. N Engl J Med. 1984;311(12):760–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Wolf Jr JS, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008;179(4):1379–90.CrossRefPubMedGoogle Scholar
  49. 49.
    Xu H, Zisman AL, Coe FL, Worcester EM. Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacother. 2013;14(4):435–47.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of UrologyStevan Streem Center for Endourology & Stone Disease, Glickman Urological & Kidney Institute, Cleveland Clinic FoundationClevelandUSA

Personalised recommendations